Joint (NASDAQ:JYNT) Upgraded by StockNews.com to “Buy”

Joint (NASDAQ:JYNT) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Monday.

A number of other equities analysts have also weighed in on JYNT. TheStreet lowered Joint from a “c-” rating to a “d” rating in a research report on Thursday, March 7th. B. Riley upped their target price on Joint from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Roth Mkm reaffirmed a “buy” rating and set a $16.00 target price (up from $13.00) on shares of Joint in a research report on Friday. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Joint presently has a consensus rating of “Moderate Buy” and an average price target of $22.00.

Joint Stock Down 2.0 %

JYNT traded down $0.33 during trading on Monday, hitting $15.79. The company’s stock had a trading volume of 143,009 shares, compared to its average volume of 90,058. Joint has a twelve month low of $7.31 and a twelve month high of $16.35. The stock’s fifty day moving average price is $12.17 and its 200-day moving average price is $10.21. The firm has a market capitalization of $235.90 million, a P/E ratio of -21.05 and a beta of 1.58.

Joint (NASDAQ:JYNT) last issued its earnings results on Thursday, March 7th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.04. Joint had a positive return on equity of 3.94% and a negative net margin of 9.24%. The company had revenue of $30.61 million for the quarter, compared to analyst estimates of $29.63 million. Equities research analysts expect that Joint will post 0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Joint

Institutional investors have recently bought and sold shares of the stock. Quantbot Technologies LP grew its holdings in Joint by 345.0% during the third quarter. Quantbot Technologies LP now owns 4,170 shares of the company’s stock worth $37,000 after buying an additional 3,233 shares in the last quarter. Barclays PLC increased its position in shares of Joint by 29.4% during the 3rd quarter. Barclays PLC now owns 13,725 shares of the company’s stock valued at $123,000 after purchasing an additional 3,119 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Joint by 43.3% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 16,506 shares of the company’s stock valued at $148,000 after purchasing an additional 4,987 shares during the last quarter. Avondale Wealth Management increased its position in shares of Joint by 192.3% during the 1st quarter. Avondale Wealth Management now owns 19,000 shares of the company’s stock valued at $248,000 after purchasing an additional 12,500 shares during the last quarter. Finally, WINTON GROUP Ltd purchased a new stake in shares of Joint during the 3rd quarter valued at $179,000. Institutional investors own 76.88% of the company’s stock.

Joint Company Profile

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.